Beyond symptom relief, a breakthrough device designed to treat the underlying cause of COPD with Chronic Bronchitis

Who qualifies for our clinical trial?

?

Beyond symptom relief, a breakthrough device designed to treat the underlying cause of COPD with Chronic Bronchitis

?

Introduction to RejuvenAir^®

9 million Americans struggle with the debilitating symptoms of COPD with Chronic Bronchitis.¹ The RejuvenAir System offers a unique solution that is aimed at treating the underlying cause of the disease; something no drug or device on the market does today.

The RejuvenAir System is a revolutionary cryosurgical device which applies a precise thermal dose or “metered cryospray” of extremely cold, -196°C liquid nitrogen to targeted areas within the lungs through a minimally invasive, often outpatient or same-day bronchoscopic procedure.

^{1. American Lung Association.}

CAUTION: Investigational device. Limited by Federal law to investigational use.

About COPD with Chronic Bronchitis

Chronic Bronchitis is the largest disease subset of Chronic Obstructive Pulmonary Disease (COPD).

Unlike common Bronchitis, which is acute and clears up quickly, Chronic Bronchitis (CB) is characterized by a long-term productive cough, breathlessness and/or wheezing as well as a tight chest sensation.

The persistent cough itself can be debilitating. Patients with Chronic Bronchitis often avoid social situations and give up activities, further contributing to a decline in overall well-being and quality of life. While current medications help alleviate symptoms, they don’t address the underlying cause of the disease and are largely ineffective.

Learn about our Clinical Trial

How Metered Cryospray Works

In Chronic Bronchitis patients, the airways have been damaged. Cilia, the tiny hair-like cells lining the lungs that help move mucus and debris out of the airway, become dysfunctional, inducing an overabundance of goblet cells which over produce mucus. The combination of these factors contributes to inflammation, which makes it difficult to breathe.

The RejuvenAir System delivers small, metered doses of cryogen spray which flash freeze the surface area of damaged airways. Diseased cells are destroyed, leaving behind the extra-cellular structure that allows for new healthy cells, including cilia and mucus-producing goblet cells, to repopulate.

RejuvenAir rejuvenates the airways.

How Metered Cryospray Works

-196° C flash freeze causes instant cell death

Preservation of extracellular matrix (ECM)

Intact ECM enables healing with limited scarring and fibrosis

In Chronic Bronchitis patients, the airways have been damaged. Cilia, tiny hair-like cells lining the lungs that help move mucus and debris out of the airway become dysfunctional, inducing an overabundance of goblet cells which over produce mucus. The combination of these factors contributes to inflammation, which makes it difficult to breathe.

The RejuvenAir System delivers small, metered doses of cryogen spray which flash freeze the surface area of damaged airways. Diseased cells are destroyed, leaving behind the extra-cellular structure that allows for new healthy cells, including cilia and mucus-producing goblet cells, to repopulate.

RejuvenAir rejuvenates the airways.

Find out if you qualify

To proceed, select the participating study center nearest to you on the map. You will be taken to the www.spray-cb.com website. Here you can watch an educational video, complete a short questionnaire and, if qualified, register your details.

Title	Address	Description
Temple University	1801 N Broad St, Philadelphia, PA 19122, USA	ENROLLING Principal Investigator: Dr. G.J. Criner, Interventional Pulmonology /Pulmonary Care.
UC Davis Medical Center	2279 45th St, Sacramento, CA 95817, USA	ENROLLING Principal Investigator: Dr. Ken Yoneda, Interventional Pulmonology /Pulmonary Care
NYU Langone Medical Center	550 1st Avenue, New York, NY 10016, USA	ENROLLING Principal Investigator: Dr. Samaan Rafeq, Interventional Pulmonology /Pulmonary Care
UT Southwestern Medical Center	5939 Harry Hines Blvd, Dallas, TX 75390, USA	ENROLLING Principal Investigator: Dr. Muhanned Abu-Hijleh, Interventional Pulmonology /Pulmonary Care
El Camino Hospital	701 E El Camino Real, Mountain View, CA 94040, USA	ENROLLING Principal Investigator: Dr. Ganesh Krishna, Interventional Pulmonology /Pulmonary Care
Beth Israel Deaconess Medical Center	185 Pilgrim Rd, Boston, MA 02215, USA	NOT YET ENROLLING
Sarasota Memorial Hospital	1700 S Tamiami Trail, Sarasota, FL 34239, USA	ENROLLING Principal Investigator: Dr. Joseph Seaman, Interventional Pulmonology /Pulmonary Care
Medical University of South Carolina	96 Jonathan Lucas St, Charleston, SC 29425, USA	ENROLLING Principal Investigator: Dr. Charlie Strange, Interventional Pulmonology /Pulmonary Care
Duke University School of Medicine	Durham, NC, USA	ENROLLING Principal Investigator: Dr. Wahidi, Interventional Pulmonology /Pulmonary Care
Advanced Pulmonary Research Institute	13005 Southern Blvd, Loxahatchee, FL 33470, USA	NOT YET ENROLLING
Henry Ford Hospital	2799 W Grand Blvd, Detroit, MI 48202, USA	NOT YET ENROLLING
University Of Wisconsin Hospital	Highland Ave, Madison, WI, USA	NOT YET ENROLLING
Louisiana State University Medical Center	Shreveport, LA 71103, USA	NOT YET ENROLLING
Norton Pulmonary Specialists	E Broadway, Louisville, KY 40202, USA	NOT YET ENROLLING
Ohio State University	Davis Heart and Lung Research Institute, 473 W 12th Ave, Columbus, OH 43210, USA	ENROLLING Principal Investigator: Dr. Christian Ghattas, Interventional Pulmonology /Pulmonary Care
Spectrum Health	4100 Lake Dr SE, Grand Rapids, MI 49546, USA	NOT YET ENROLLING
Johns Hopkins Hospital	600 N Wolfe St, Baltimore, MD 21287, USA	ENROLLING Principal Investigator: Dr. David Feller-Kopman, Bronchoscopy & Interventional Pulmonology

About Us

CSA Medical is committed to developing spray cryotherapy devices that improve the lives of people suffering from COPD with Chronic Bronchitis. We are advancing our core liquid nitrogen spray technology to target the underlying cause of Chronic Bronchitis – the over production of mucus and damaged cilia within the airways. By targeting and destroying these damaged cells without creating scar tissue, the body can begin the rapid regrowth of new, healthy normal functioning cells in the lung.

CSA Medical is currently conducting clinical studies with the RejuvenAir System. The clinical study aims to evaluate the effectiveness of the RejuvenAir System to reduce mucous production, cough, and inflammation in the Chronic Bronchitis patient population and to determine the extent of improvement in their overall health and quality of life.

News & Resources

CSA Medical Announces Metered Cryospray with the RejuvenAir® System for the treatment of Chronic Bronchitis Featured at the 21st World Congress of Bronchology and Interventional Pulmonology

Nov 23, 2020

The RejuvenAir System is designed to address the underlying cause of COPD with Chronic Bronchitis and enable rejuvenative healing of the airways BOSTON, Nov. 23, 2020 -- CSA Medical, Inc., today announced metered cryospray utilizing the RejuvenAir® System for the...

CSA Medical Announces Enrollment Milestone in a Mechanism of Action Study utilizing the RejuvenAir® System for COPD Patients with Chronic Bronchitis

Nov 11, 2020

This study will provide a scientific rationale for the remodeling response and clinical improvements identified in the feasibility study Boston, MA –November 11, 2020: CSA Medical, Inc., today announced that over half of the subjects in a 32 patient study,...

CSA Medical Announces First Procedure in the SPRAY-CB Pivotal Trial for the Treatment of Chronic Bronchitis

Oct 22, 2020

The SPRAY-CB trial marks the first pivotal study of a medical device therapy targeting the underlying cause of Chronic Bronchitis. Boston,MA. – October 22, 2020: CSA Medical Inc., a developer of medical devices advancing the power of liquid nitrogen spray cryotherapy,...

Beyond symptom relief, a breakthrough device designed to treat the underlying cause of COPD with Chronic Bronchitis